Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SRPK1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SRPK1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SRPK1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SRPK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SRPK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SRPK1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SRPK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SRPK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SRPK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SRPK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004348420 | Oral cavity | OSCC | regulation of RNA splicing | 108/7305 | 148/18723 | 4.25e-17 | 3.69e-15 | 108 |
GO:002261820 | Oral cavity | OSCC | ribonucleoprotein complex assembly | 146/7305 | 220/18723 | 1.53e-16 | 1.23e-14 | 146 |
GO:00070592 | Oral cavity | OSCC | chromosome segregation | 206/7305 | 346/18723 | 5.82e-15 | 3.76e-13 | 206 |
GO:001907920 | Oral cavity | OSCC | viral genome replication | 95/7305 | 131/18723 | 6.35e-15 | 4.02e-13 | 95 |
GO:005079220 | Oral cavity | OSCC | regulation of viral process | 109/7305 | 164/18723 | 8.95e-13 | 4.10e-11 | 109 |
GO:004802420 | Oral cavity | OSCC | regulation of mRNA splicing, via spliceosome | 74/7305 | 101/18723 | 2.66e-12 | 1.09e-10 | 74 |
GO:190390020 | Oral cavity | OSCC | regulation of viral life cycle | 97/7305 | 148/18723 | 5.34e-11 | 1.67e-09 | 97 |
GO:004852417 | Oral cavity | OSCC | positive regulation of viral process | 51/7305 | 65/18723 | 9.56e-11 | 2.90e-09 | 51 |
GO:004506917 | Oral cavity | OSCC | regulation of viral genome replication | 62/7305 | 85/18723 | 2.14e-10 | 6.04e-09 | 62 |
GO:00069974 | Oral cavity | OSCC | nucleus organization | 85/7305 | 133/18723 | 5.12e-09 | 1.12e-07 | 85 |
GO:00450708 | Oral cavity | OSCC | positive regulation of viral genome replication | 25/7305 | 30/18723 | 8.09e-07 | 1.12e-05 | 25 |
GO:00450717 | Oral cavity | OSCC | negative regulation of viral genome replication | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
GO:00485259 | Oral cavity | OSCC | negative regulation of viral process | 56/7305 | 92/18723 | 1.77e-05 | 1.72e-04 | 56 |
GO:00002456 | Oral cavity | OSCC | spliceosomal complex assembly | 45/7305 | 79/18723 | 9.13e-04 | 4.81e-03 | 45 |
GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRPK1 | SNV | Missense_Mutation | | c.1640N>T | p.Gly547Val | p.G547V | Q96SB4 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
SRPK1 | SNV | Missense_Mutation | rs773631165 | c.1756N>A | p.Tyr586Asn | p.Y586N | Q96SB4 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SRPK1 | SNV | Missense_Mutation | rs371124622 | c.251G>A | p.Arg84Gln | p.R84Q | Q96SB4 | protein_coding | deleterious(0.01) | benign(0.098) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SRPK1 | SNV | Missense_Mutation | | c.154G>C | p.Asp52His | p.D52H | Q96SB4 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRPK1 | SNV | Missense_Mutation | rs773631165 | c.1756N>A | p.Tyr586Asn | p.Y586N | Q96SB4 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
SRPK1 | SNV | Missense_Mutation | novel | c.781G>C | p.Asp261His | p.D261H | Q96SB4 | protein_coding | tolerated(0.09) | possibly_damaging(0.889) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
SRPK1 | SNV | Missense_Mutation | | c.1019A>G | p.Gln340Arg | p.Q340R | Q96SB4 | protein_coding | tolerated(0.47) | benign(0.015) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRPK1 | SNV | Missense_Mutation | | c.1462G>A | p.Ala488Thr | p.A488T | Q96SB4 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
SRPK1 | SNV | Missense_Mutation | novel | c.553N>G | p.Pro185Ala | p.P185A | Q96SB4 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
SRPK1 | SNV | Missense_Mutation | rs749597130 | c.1912N>G | p.Pro638Ala | p.P638A | Q96SB4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | TAE-684 | TAE-684 | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | DOVITINIB | DOVITINIB | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | SNS-314 | SNS-314 | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | PF-562271 | PF-00562271 | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | ALISERTIB | ALISERTIB | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | LINIFANIB | LINIFANIB | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | Sphinx | | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | ZINC959121 | | |
6732 | SRPK1 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565868 | | |